STOCK TITAN

Cadrenal Therapeutics (CVKD) SEC Filings, Jul-Aug 2025

CVKD NASDAQ

Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.

The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.72%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
proxy

FAQ

How many Cadrenal Therapeutics (CVKD) SEC filings are available on StockTitan?

StockTitan tracks 92 SEC filings for Cadrenal Therapeutics (CVKD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cadrenal Therapeutics (CVKD)?

The most recent SEC filing for Cadrenal Therapeutics (CVKD) was filed on November 17, 2026.